Trump DOJ's Delays on Abortion Pill Lawsuits Endanger Women and Babies
Source: Jordan Boyd. "Trump DOJ Demands Pause On Another Abortion Pill Lawsuit." March 16, 2026. thefederalist.com
The Gist
The author argues that Trump's Justice Department is wrong to ask courts to pause lawsuits against abortion pills while the FDA does a safety review. She believes these pills are dangerous and that waiting for the slow FDA process will harm women and kill unborn babies unnecessarily.
Conclusion
The Trump administration's DOJ is wrongfully prioritizing bureaucratic process over immediate safety concerns by demanding pauses on state lawsuits challenging FDA's dangerous abortion pill permissions
Premises
- The FDA's 2023 mifepristone permissions allow dangerous mail-order abortions without medical oversight in any state
- More than one in 10 women who take mifepristone suffer serious adverse events like hemorrhage or infection
- The FDA's promised safety review is making no meaningful progress, with officials admitting they're 'not even reviewing any data yet'
- Pro-life states need immediate legal intervention to properly enforce their chemical abortion prohibitions and protect their citizens
- Every month of delay results in approximately 1,000 unborn deaths in Louisiana alone and 700+ women requiring emergency room visits
- Even if the FDA acted immediately, regulatory processes wouldn't provide relief until 2027, leaving women and babies vulnerable for years
Assumptions
- Mifepristone poses significant safety risks that justify immediate legal intervention
- State governments have legitimate authority to challenge federal drug approvals that affect their citizens
- Unborn lives have moral status that should be legally protected
- The Trump administration should prioritize pro-life policy goals over federal agency deference
- Emergency judicial relief is more appropriate than waiting for administrative review when lives are at stake